Cancer metastasis
Prognostic Factors Identified for Metastatic Castration-Resistant Prostate Cancer Undergoing Radioligand Therapy
New research conducted at the Department of Nuclear Medicine, Balikesir Ataturk City Hospital in Turkiye has shed light on the prognostic factors for metastatic castration-resistant prostate cancer (mCRPC) patients undergoing 177Lu-PSMA-617 radioligand therapy. The study retrospectively examined 31 patients with median age 69 (57-80) years, who received treatment between 2021